RESEARCH TRIANGLE PARK, N.C., Dec. 5, 2011 /PRNewswire/ -- A dedicated and experienced Max Neeman team has been set-up to conduct Biosimilar studies for evaluation and efficacy of products. The company expanded into this arena because India has demonstrated the greatest acceptance of Biosimilars reflected by over 50 biopharmaceutical brands getting marketing approval. CEO, Dr. Ajoy Kumar firmly believes in a responsive, knowledge-based organization to meet client's needs.
The Indian Biosimilars market in 2008 was estimated to be worth approximately $200 million by Universal Consulting [India-based market research firm]. This is forecasted to reach $580 million by 2012 due to two key factors: relative cost advantage of Biosimilars development versus competitors elsewhere and lower regulatory requirements for establishing bioequivalence [which also helps to keep development costs low]. Currently the manufacture and marketing of Biosimilars in India is governed by the Environment Protection Act of 1970 and the Drugs and Cosmetic Act.
About Max Neeman International
Max Neeman International is a leading Indian CRO. Our specialty is that we offer services for the successful conduct of Phase II-IV clinical and device trials for small and mid-sized international and national Pharmaceutical, Biotechnology, Medical Device and Nutraceutical companies in compliance with ICH GCP standards. Operational since 2001, Max Neeman is also an ISO 9001:2008 & ISO 27001:2005 certified CRO for Monitoring, Site Management and Data Management Services. The company is presently active in 31 cities with 6 regional offices. For more information, please contact Donald Swankie, Vice President Business Development at +1.919.424.3345 / firstname.lastname@example.org or visit www.neeman-medical.com.
SOURCE Max Neeman International